cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-2-46-51cardiovascular-154Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАCORONARY HEART DISEASEОЦЕНКА ПОЛИМОРФИЗМА ГЕНОВ ЛИПИД-ТРАНСПОРТНОЙ СИСТЕМЫ И I/D ПОЛИМОРФИЗМА ГЕНА АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА У БОЛЬНЫХ НЕСТАБИЛЬНОЙ СТЕНОКАРДИЕЙ УЗБЕКСКОЙ НАЦИОНАЛЬНОСТИ С СЕМЕЙНЫМ АНАМНЕЗОМ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦАLIPID TRANSPORT GENETIC POLYMORPHISM AND ANGIOTENSIN-CONVERTING ENZYME I/D GENETIC POLYMORPHISM IN UZBEK PATIENTS WITH UNSTABLE ANGINA AND CORONARY HEART DISEASE IN FAMILY HISTORYКурбановР. Д.KurbanovR. D.

д. м.н., профессор, директор

БекметоваФ. М.BekmetovaF. M.

к. м.н., с. н.с. лаборатории ИБС

ШекА. Б.ShekA. B.

д. м.н., зам. директора

КанЛ. Э.KanL. E.

стажёр-исследователь лаборатории ИБС

Tел.: +998971548568 

kanlilia@mail.ruХашимовШ. У.KhashimovSh. U.

м. н.с. лаборатории ИБС

Республиканский специализированный центр кардиологии, ТашкентRepublican Specialised Centre of Cardiology, Tashkent2013200420131224651Copyright © Курбанов Р.Д., Бекметова Ф.М., Шек А.Б., Кан Л.Э., Хашимов Ш.У., 20132013Курбанов Р.Д., Бекметова Ф.М., Шек А.Б., Кан Л.Э., Хашимов Ш.У.Kurbanov R.D., Bekmetova F.M., Shek A.B., Kan L.E., Khashimov S.U.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/154Цель

Цель. Изучить влияние семейного анамнеза ишемической болезни сердца (ИБС) на распределение полиморфизма генов аполипопротеинов (апо) А1, В и Е липид-транспортной системы и I/D полиморфизма гена ангиотензин-превращающего фермента (АПФ) у больных нестабильной стенокардией (НС) узбекской национальности.

Материал и методы

Материал и методы. Обследованы 125 больных узбекской национальности с НС из них I группа (гр.) (n=63) имела отягощенный семейный анамнез и II гр. (n=62) без отягощенного анамнеза. Гр. контроля — 58 здоровых лиц. G-A полиморфизм гена апоA1, —516C/T полиморфизма гена апоB, ε2/ε3/ε4 полиморфизм гена апоE и I/D полиморфизм гена АПФ определяли с использованием набора реагентов Diatom TM DNA Prep 200 (производство ООО «Лаборатория ИзоГен»).

Результаты

Результаты. При изучении распределения «повреждающих» аллелей изучаемых генов среди больных НС в сравнении со здоровыми, выявлена большая распространенность носительства аллели А апоA1 (OР 3,63, 95% ДИ 1,63–8,04, p=0,002). При сравнительном анализе II гр. с гр. сравнения распределение «повреждающих» аллелей достоверно не различалось, тогда как в I гр. отмечалось достоверно большее накопление аллелей «А» G-A полиморфизма гена апоА1 (OР 5,99, 95% ДИ 2,52–14,24, р=0,001), аллели «ε4» гена апоЕ (OР 2,91, 95%, ДИ 1,12–7,62, р=0,044), аллели «D» I/D полиморфизма гена AПФ (ОР 2,88, 95% ДИ 1,33–6,27, р=0,024). При этом не было выявлено различий в частоте носительства «Т» аллели — 516C/T полиморфизма гена апоВ.

Заключение

Заключение. Наличие семейного анамнеза ИБС среди лиц узбекской национальности с НС ассоциируется с накоплением «повреждающих» аллелей: «А» (М1-) G-A полиморфизма гена апоА1, «ε4» гена апоЕ, и аллели «D» I/D полиморфизма гена АПФ. При этом не выявлено различий в частоте носительства «Т» аллели –516C/T полиморфизма гена апоВ. 

Aim

Aim. To study the impact of coronary heart disease (CHD) in family history on the genetic polymorphisms of apolipoprotein (apo) A1, B, and E and angiotensin-converting enzyme (ACE) in Uzbek patients with unstable angina (UA).

Material and methods

Material and methods. The study included 125 Uzbek patients with UA. Group I (n=63) had CHD in family history, Group II (n=62) had no CHD in family history, and the control group included 58 healthy individuals. The following genetic polymorphisms were investigated, using the Diatom TM DNA Prep 200 kit (IsoGen Laboratory Ltd.): apoA1 G-A polymorphism; apoB –516C/T polymorphism; apoE ε2/ε3/ε4 polymorphism, and ACE I/D polymorphism.

Results

Results. In UA patients, compared to healthy controls, the prevalence of apoA1 A allele was significantly higher (odds ratio (OR) 3,63; 95% confidence interval (CI) 1,63–8,04; p=0,002). The distribution of the “damaging” alleles was similar in Group II and the control group, while Group I demonstrated a significantly higher prevalence of A alleles of the apoA1 G-A polymorphism (OR 5,99; 95% CI 2,52–14,24; p=0,001); ε4 allele of the apoE gene (OR 2,91; 95% CI 1,12–7,62; p=0,044); and D allele of the ACE I/D polymorphism (OR 2,88; 95% CI 1,33–6,27; p=0,024). At the same time, there was no marked difference in the distribution of the T allele of the apoB –516C/T polymorphism.

нестабильная стенокардияполиморфизм гена ангиотензин-превращающего ферментасемейный анамнез ишемической болезни сердцакомплекс интима-медиаunstable anginaangiotensin-converting enzyme genetic polymorphismcoronary heart disease in family historyintima-media thicknessReferencesVan’t Hooft FM, Jormsjö S, Lundahl B, et al. A functional polymorphism in the apolipoprotein B promoter that influences the level of plasma low density lipoprotein. J Lipid Res 1999; 40: 1686–94.Van’t Hooft FM, Jormsjö S, Lundahl B, et al. A functional polymorphism in the apolipoprotein B promoter that influences the level of plasma low density lipoprotein. J Lipid Res 1999; 40: 1686–94.Zou Yangchun, Hu Dayi, Yang Xinchun, et al. Relationships among apolipoprotein A1 gene polymorphisms, lipid levels and coronary atherosclerosis disease. Chinese Medical J 2003; 116: 5: 665–8.Zou Yangchun, Hu Dayi, Yang Xinchun, et al. Relationships among apolipoprotein A1 gene polymorphisms, lipid levels and coronary atherosclerosis disease. Chinese Medical J 2003; 116: 5: 665–8.Gerdes LU, Jeune B, Ranberg KA, et al. Estimation of apolipoprotein E genotype specific relative mortality from the distribution of genotypes in centenarians and middle-aged men: Apolipoprotein E gene is a «frailty gene», not a «longevity gene» Genetic Epidemiol 2000; 19: 202–10.Gerdes LU, Jeune B, Ranberg KA, et al. Estimation of apolipoprotein E genotype specific relative mortality from the distribution of genotypes in centenarians and middle-aged men: Apolipoprotein E gene is a «frailty gene», not a «longevity gene» Genetic Epidemiol 2000; 19: 202–10.Jeenah M, Kessling A, Miller N, Humphries SE. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990; 7: 233–41.Jeenah M, Kessling A, Miller N, Humphries SE. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990; 7: 233–41.Pagani F, Sidoli A, Giudici GA, et al. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990; 31: 1371–7.Pagani F, Sidoli A, Giudici GA, et al. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990; 31: 1371–7.Civeira F, Pocovi M, Cenarro A, et al. Adenine for guanine substitution –78 base pairs to the apolipoprotein (APO) A-I gene: relation with high-density lipoprotein cholesterol and apoA-I concentrations. Clin Genet 1993; 44: 307–12.Civeira F, Pocovi M, Cenarro A, et al. Adenine for guanine substitution –78 base pairs to the apolipoprotein (APO) A-I gene: relation with high-density lipoprotein cholesterol and apoA-I concentrations. Clin Genet 1993; 44: 307–12.Wang XL, Liu SX, McCredie RM, Wilcken DEL. Polymorphisms at the 5‘-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996; 98: 372–7.Wang XL, Liu SX, McCredie RM, Wilcken DEL. Polymorphisms at the 5‘-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996; 98: 372–7.Matsunaga A, Sasaki J, Mori T, et al. Apolipoprotein A-I gene promoter polymorphism in patients with coronary artery disease and healthy controls. Nutr Metab Cardiovasc Dis 1995; 5: 269–75.Matsunaga A, Sasaki J, Mori T, et al. Apolipoprotein A-I gene promoter polymorphism in patients with coronary artery disease and healthy controls. Nutr Metab Cardiovasc Dis 1995; 5: 269–75.. Ali I Albahrani, Jannete Usher J, Mohammed Alkindi, et al. Apolipoprotein A1–75 G/A (M1-) polymorphism and Lipoprotein (a) Anti- versus Pro-Atherogenic properties. Lipids in Health and Disease 2007; 6: 19.. Ali I Albahrani, Jannete Usher J, Mohammed Alkindi, et al. Apolipoprotein A1–75 G/A (M1-) polymorphism and Lipoprotein (a) Anti- versus Pro-Atherogenic properties. Lipids in Health and Disease 2007; 6: 19.Heng CК, Low PS, Saha N. Variations in the promoter region of the apolipoprotein A-1 gene influence plasma lipoprotein (a) levels in Asian Indian neonates from Singapore. Pediatr Res 2001; 49: 514–8.Heng CК, Low PS, Saha N. Variations in the promoter region of the apolipoprotein A-1 gene influence plasma lipoprotein (a) levels in Asian Indian neonates from Singapore. Pediatr Res 2001; 49: 514–8.Requero JR, Cubero GI, Batalla A, et al. Apolipoprotein AI gene polymorphisms and risk of early Coronary disease. Cardiology 1998; 90: 231–5.Requero JR, Cubero GI, Batalla A, et al. Apolipoprotein AI gene polymorphisms and risk of early Coronary disease. Cardiology 1998; 90: 231–5.Song Y, Stampfer MJ, Liu S. Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease Ann Int Med 2004; 141: 2: 137–47.Song Y, Stampfer MJ, Liu S. Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease Ann Int Med 2004; 141: 2: 137–47.Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study Circulation 2000; 101: 1366–71.Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study Circulation 2000; 101: 1366–71.Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J 2007; 28: 16: 1977–83.Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J 2007; 28: 16: 1977–83.Van Geel PP, Pinto YM, Zwinderman AH, et al. Synergistic effects of angiotensin converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on ischaemic events XX Congress of the European society of Cardiology 2001; Abstract: 386.Van Geel PP, Pinto YM, Zwinderman AH, et al. Synergistic effects of angiotensin converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on ischaemic events XX Congress of the European society of Cardiology 2001; Abstract: 386.

The authors declare that there are no conflicts of interest present.